business
Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO
Avalyn Pharma Inc. shares jumped 44% in its trading debut, after the biopharmaceutical company raised $300 million in an upsized US initial public offering.
Read full story on Bloomberg Markets → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Bloomberg Markets alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop